Clinical Trial Update: Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update reports on the efficacy and safety of Acthar Gel (repository corticotropin injection) for refractory cutaneous manifestations of…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis
• Juvenile Dermatomyositis

Drugs mentioned

• Acthar Gel (repository corticotropin injection)

Snippet

Sponsor: The Cleveland Clinic | Conditions: Dermatomyositis, Juvenile Dermatomyositis | Phase 4 | Status: COMPLETED | Results posted: 2024-06-11